Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.21.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Statement of Cash Flows [Abstract]    
Net loss $ (15,603,716) $ (18,498,341)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 867,000 949,006
Stock-based compensation 668,072 397,099
Non-cash interest expense 155,738 1,421,655
Change in fair value of preferred stock warrant liability 743,837 71,635
Allowance for doubtful accounts (2,941)
Deferred rent (210,010) (217,756)
Accounts receivable (401,737) (126,200)
Prepaid expenses and other current assets (646,925) (38,950)
Deposits (40,882)
Accounts payable (396,863) 373,747
Accrued expenses and other current liabilities 497,656 530,280
Deferred revenue (71,905) 644,961
Customer deposits (108,750)
Net cash used in operating activities (14,398,853) (14,645,437)
Cash flows from investing activities:    
Purchase of property and equipment (647,015) (823,013)
Net cash used in investing activities (647,015) (823,013)
Cash flows from financing activities:    
Cash paid in connection with the Merger, net of cash acquired (46,044)
Payment to unaccredited investors of Augmedix Operating Corporation (555,174)
Proceeds from notes payable 2,180,300
Repayment of notes payable (1,357,837)
Proceeds from sale of common stock 27,416,565
Proceeds from issuance of convertible preferred stock 499,999 15,271,440
Proceeds from issuance of convertible notes payable 3,303,535
Payment of financing costs (3,159,488) (52,893)
Proceeds from exercise of stock options 80,487 3,533
Net cash provided by financing activities 26,416,645 17,167,778
Effect of exchange rate changes on cash and restricted cash (1,176) (10,397)
Net increase in cash and restricted cash 11,369,601 1,688,931
Cash and restricted cash at beginning of year 11,603,385 9,914,454
Cash and restricted cash at end of year 22,972,986 11,603,385
Supplemental disclosure of cash flow information:    
Cash paid during the year for interest 1,265,608 1,367,929
Supplemental schedule of non-cash investing and financing activities:    
Conversion of convertible preferred stock to shares of common stock 54,242,264
Amounts due to unaccredited investors of Augmedix Operating Corporation 31,527
Financing fees in accrued expenses 5,000
Issuance of convertible preferred stock in exchange for convertible notes payable and accrued interest 3,319,283
Beneficial conversion feature related to convertible notes payable $ 1,078,769